Pfizer’s Acquisition Of Angiosyn Brings Complementary Product To Macugen
This article was originally published in The Pink Sheet Daily
Executive Summary
Purchase of biotech firm provides Pfizer with another potential ophthalmic agent to complement the age-related macular degeneration therapy Macugen. The deal calls for Pfizer to pay Angiosyn shareholders up to $527 mil., as well as royalties on future product sales.